Related Experiment Video
Updated: Apr 30, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction
Dimitrios Alexopoulos1, Ioanna Xanthopoulou1, John Goudevenos2
1Department of Cardiology, Patras University Hospital, Patras, Greece.
Insights
Effective antiplatelet therapy is crucial for ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention. Stronger P2Y12 inhibitor regimens show faster platelet inhibition but lack proven anti-ischemic superiority over standard clopidogrel in STEMI.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Effective antiplatelet therapy is critical for ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).
- Potent P2Y12 inhibitors like prasugrel and ticagrelor offer superior platelet inhibition compared to standard clopidogrel.
- The clinical benefit of enhanced platelet inhibition in STEMI patients undergoing primary PCI remains under investigation.
Purpose of the Study:
- To evaluate the anti-ischemic efficacy of potent P2Y12 inhibitors versus standard clopidogrel in STEMI patients.
- To examine the role and variability of platelet reactivity in STEMI patients on antiplatelet therapy.
- To assess the safety and efficacy of different antiplatelet strategies in the context of primary PCI.
Main Methods:
- Review of clinical trials and clinical practice data on oral and intravenous P2Y12 inhibitors in STEMI.
- Analysis of factors influencing platelet reactivity, including genetic predisposition and testing methods.
- Assessment of anti-ischemic and bleeding outcomes associated with various antiplatelet regimens.
Main Results:
- Stronger P2Y12 inhibitor regimens provide faster and more potent platelet inhibition than standard clopidogrel.
- Statistically significant anti-ischemic superiority of potent regimens over standard clopidogrel has not been definitively proven in primary PCI for STEMI.
- Platelet reactivity is variable and influenced by multiple factors, impacting treatment effectiveness.
Conclusions:
- While potent P2Y12 inhibitors offer enhanced platelet inhibition, their definitive anti-ischemic superiority in STEMI patients undergoing primary PCI requires further robust evidence.
- The clinical utility of oral antiplatelet agents in STEMI is debated due to potential delays in onset of action.
- Careful monitoring for bleeding risk is essential when considering intensified antiplatelet strategies in STEMI.
Abstract:
In ST-segment elevation myocardial infarction (STEMI), an effective antiplatelet treatment adjunctive to primary percutaneous coronary intervention is of utmost importance. High dose of clopidogrel, prasugrel, or ticagrelor provides a faster, more potent, and more consistent platelet inhibition than standard clopidogrel. Oral P2Y12 inhibitors have been studied in large clinical trials and are in use in clinical practice. Intravenously administered P2Y12 inhibitors such as cangrelor have also been tested. However, statistically significant anti-ischemic superiority of stronger platelet inhibition regimens versus standard clopidogrel has not been proved exclusively in patients receiving primary percutaneous coronary intervention. Whether orally administered antiplatelet agents suffice in patients with STEMI has been recently disputed, mainly because of their delayed onset of action. Platelet reactivity variability before P2Y12 blockade and its evolution over time, genetic predisposition, antiplatelet agent used, timing, and method of platelet function testing significantly affect the rates of high on-treatment platelet reactivity. Although ominous signs of greater bleeding potential of stronger antiplatelet regimens have not appeared in STEMI, this should be carefully tested.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...